Trxade Group, Inc. (NASDAQ:MEDS) – Equities researchers at Taglich Brothers issued their Q1 2022 EPS estimates for Trxade Group in a research note issued to investors on Monday, April 5th. Taglich Brothers analyst H. Halpern anticipates that the company will post earnings of $0.02 per share for the quarter. Taglich Brothers also issued estimates for Trxade Group’s Q2 2022 earnings at $0.09 EPS, Q3 2022 earnings at $0.12 EPS, Q4 2022 earnings at $0.07 EPS and FY2022 earnings at $0.30 EPS.

A number of other research firms have also recently weighed in on MEDS. Colliers Securities reissued a “buy” rating and set a $10.00 price objective on shares of Trxade Group in a report on Tuesday, March 30th. Maxim Group assumed coverage on shares of Trxade Group in a report on Friday, February 26th. They set a “buy” rating on the stock. Finally, Zacks Investment Research cut shares of Trxade Group from a “hold” rating to a “sell” rating in a report on Wednesday, March 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Trxade Group currently has an average rating of “Buy” and a consensus price target of $10.81.

Shares of NASDAQ:MEDS opened at $5.11 on Wednesday. The company has a quick ratio of 16.81, a current ratio of 19.89 and a debt-to-equity ratio of 0.02. Trxade Group has a fifty-two week low of $4.02 and a fifty-two week high of $8.25. The firm’s 50 day moving average price is $6.37 and its 200 day moving average price is $5.75. The stock has a market cap of $41.36 million, a price-to-earnings ratio of 170.33, a price-to-earnings-growth ratio of 0.83 and a beta of 1.42.

Trxade Group (NASDAQ:MEDS) last issued its earnings results on Sunday, March 28th. The company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.21). Trxade Group had a negative net margin of 4.28% and a negative return on equity of 8.28%.

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Trxade Group by 28.9% during the third quarter. BlackRock Inc. now owns 10,426 shares of the company’s stock worth $65,000 after acquiring an additional 2,336 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Trxade Group during the fourth quarter worth approximately $212,000. Finally, National Asset Management Inc. purchased a new position in shares of Trxade Group during the fourth quarter worth approximately $454,000. Institutional investors and hedge funds own 13.13% of the company’s stock.

About Trxade Group

Trxade Group, Inc, together with its subsidiaries, operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services.

Further Reading: Systematic Risk and Investors

Earnings History and Estimates for Trxade Group (NASDAQ:MEDS)

Receive News & Ratings for Trxade Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trxade Group and related companies with's FREE daily email newsletter.